TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ANDROGEL

TESTOSTERONE Androgen Receptor Agonists
Oncology Approved 2000-02-28
3
Indications
--
Phase 3 Trials
26
Years on Market

Details

Status
Prescription
First Approved
2000-02-28
Routes
TRANSDERMAL
Dosage Forms
GEL, GEL, METERED

Companies

Active Ingredient: TESTOSTERONE

ANDROGEL Approval History

Loading approval history...

What ANDROGEL Treats

1 indications

ANDROGEL is approved for 1 conditions since its original approval in 2000. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypogonadism
Source: FDA Label

ANDROGEL Boxed Warning

SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.2 )]. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 )]. Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Admin...

🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ANDROGEL FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

AndroGel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogo...

⚠️ BOXED WARNING

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.2 )]. Children should avoid contact with unwashed or unclothed application sites in men using testos...

ANDROGEL Patents & Exclusivity

Latest Patent: Oct 2026

Patents (72 active)

US8466137 Expires Oct 12, 2026
US8466138 Expires Oct 12, 2026
US8741881 Expires Oct 12, 2026
US8754070 Expires Oct 12, 2026
US8729057 Expires Oct 12, 2026
US8759329 Expires Oct 12, 2026
US8466136 Expires Oct 12, 2026
US8486925 Expires Oct 12, 2026
+ 62 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.